NIAID Monoclonal Antibody Therapeutics for Biodefense and Emerging Infectious Diseases Workshop
March 29, 2006
Speakers
Melina Soares, U. Texas Southwestern Medical Center, Dallas
- Tarvacin ™ - Antiviral: A Novel Monoclonal Antibody Based Therapy for Enveloped Viruses
Stephen Demarest, Biogen idec
- The Intrinsic Stability of Antibodies Based on Experiment, Design, and Prediction
Renata Albrecht, CDER
- Regulatory Requirements for Clinical Development of Monoclonal Antibody Therapy for BEID
Hanan Ghantous, CDER
- Preclinical Safety Assessment for Monoclonal Antibodies for BEID
G. Mani Subramanian, Human Genome Sciences, Inc.
- Development of ABthrax, a fully human monoclonal antibody directed against Bacillus anthracis protective antigen (PA), for the treatment of inhalational anthrax
Brent Iverson and George Georgiou, Department of Chemistry and Biochemistry and the Institute for Cellular and Molecular Biology University of Texas
- Engineered Antibodies for the Treatment of Anthrax
Kris Briggs, Diversa
- Comprehensive Optimization of Antibody Therapeutics by Directed Evolution
Kathryn Stein, Macrogenics, Inc.
- Immunogenicity of Monoclonal Antibody Products (PDF)
Tibor Keler, Laura Vitale, Tom O'Neil, Diann Blanset, Geoffrey Nichol, Israel Lowy
- Properties and Development of Valortim™(MDX-1303): A potent, fully human mAbto PA for treatment of inhalational anthrax
back to top